HLS Therapeutics Announces Q3 2026 Financial Results
Q3 revenue of $14.2 million, up 5% year-over-year; Adjusted EBITDA of $5 million, up 1% year-over-ye
Q3 revenue of $14.2 million, up 5% year-over-year; Adjusted EBITDA of $5 million, up 1% year-over-ye